ChromoCure and Genome Research Group Expect Increased Worldwide Aneuploidy Research and Collaborate as a Result of Aneuploidy201
May 03 2010 - 10:38AM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) and Genome Research Group (GRG)
continue their joint expansion and increased capabilities in
response to the surge of aneuploidy/chromosomal theory of cancer
research and worldwide collaboration.
In fact, the European Molecular Biology Organization (EMBO) will
be holding their Aneuploidy2010 workshop June 19th - 23rd at and in
conjunction with the University of Edinburgh's Centre for Cell
Biology, one of nine UK-based Wellcome Trust Centres, three of
which are in Scotland.
The Wellcome Trust is a global charity dedicated to achieving
extraordinary improvements in human and animal health and the
support of the brightest minds in biomedical research and the
medical humanities.
Today EMBO has more than 1400 members in Europe and close to 90
associate members worldwide -- providing a dedicated focal point
for the vast network of molecular biology. The organization runs an
extended programme of activities ranging from fellowships, courses
and workshops to science & society activities and scientific
publications. EMBC has since grown to 27 member states including
many European Union countries and beyond.
The aim Aneuploidy2010 is to bring group leaders, Ph.D. students
and postdoctoral fellows working on chromosome segregation together
with their peers working on mechanisms and consequences of
aneuploidy. In excess of 36 world experts are already confirmed a
speakers.
Thus the overall goal is to help cell biologists better
understand key concepts and the latest results in aneuploidy in
order to help guide their future research directions, whilst also
informing those working on the applied study of aneuploidy to
ensure that they are exposed to the cutting edge of international
mitosis research.
The Mayo Clinic's recent landmark findings confirming aneuploidy
as the cause of cancer were published in the December 2009 Cancer
Cell journal. This publication has spurred increased worldwide
research by a number of respected research universities and
institutions, all of which have published similar reports in
2010.
The Company recently announced the Euro Zone launch of its
Pathologist Collaborative Research (PCR) Program in support of the
groundbreaking Project Boveri: Find the Cure Initiative; as the
companies leverage their combined technologies, research knowledge
and industry relationships.
The Company will announce programs and specifics for each
Euro-Zone country as its lead partner in the area is selected.
The Company's recently announced merger with GRG prepares the
group for a leading role in the new era of cancer research,
detection, and therapy.
Research has conclusively and irrefutably demonstrated
aneuploidy a more accurate predictor of cancer than
cytological/histological analysis or genetic marker-based
diagnostics that are the only other methods in existence today.
ChromoCure's proprietary technology and understanding of cancer
compliment GRG's non-toxic and non-invasive approaches to cancer
therapy and cure research.
The Company's focus on cancer research is further underscored by
recent major clinical publications that both validate ChromoCure's
chromosomal/aneuploidy theory of cancer and establish the company's
detection approach as the forefront of both cancer detection and
research.
GRG's advanced Therapeutic Modeling Protocols, together with
ChromoCure's landmark Chromosomal Scanning Technology, further
strengthens the Company's leadership in Cancer Detection, Therapy
and Cure by providing on-demand, real-time cancer progression
analysis to monitor and determine treatment efficacy.
The Company's recently announced merger with GRG will be of
mutual benefit in advancement of their shared objective; as a
focused Cancer Therapy and Cure Research & Development
organization. The announced merger and acquisition of GRG prepares
the group for a leading role in this new era of cancer research,
detection and therapy.
The combined entity will possess complementary detection and
therapeutic technology and protocols. Management believes the
transaction to be of significant long-term shareholder value and
furthers the Company's transition to research, technology
development, and licensing as a source of significant long-term and
recurring revenues and equity appreciation.
The Company believes its technologies provide the foundation for
significant advances in diagnosis, therapy and cure. The Company
recently announced its Therapy and Cure initiatives with Project
Boveri: Find the Cure. Shareholders can expect further updates on
research collaborations, laboratory partnerships, and research
initiatives.
The Company's goal is to establish a worldwide network of
diagnostic and research collaborations with continuous collection
of cancer specimen and test result data.
About ChromoCure ChromoCure develops and
provides proprietary cancer detection systems and related
therapeutic technologies. The Company's proprietary CS200
Chromosomal Scanner has been proven accurate and efficient in the
measurement of the unique genomic characteristic found in 100% of
all cancers and never found in normal cells. The Company's
detection technology has an effective accuracy of 100% for all
cancers at all stages. The Company believes its technology will
become the worldwide gold standard for cancer detection,
progression measurement, and research for both therapy and cure.
The Company also applies its technology and knowledge to cancer
cure and therapeutics research.
About Genome Research Group The Genome
Research Group develops and provides proprietary cancer detection
systems and related therapeutic technologies. The Company's
proprietary cancer detection system locates and measures unique
genomic characteristic found in 100% of all cancers and never found
in normal cells. The Company's detection technology has a proven
and effective accuracy of 100% for all cancers at all stages. The
Company's proprietary Therapeutic Modeling Protocols provide
statistical modeling and prediction tools for the measurement and
monitoring of cancer progression and remission. The Company also
applies its technology and knowledge to cancer cure and
therapeutics research. GRG owns proprietary techniques for
non-toxic and non-invasive cancer therapy utilizing hypothermic
modulation and resonance. GRG's advanced Therapeutic Modeling and
Treatment Protocols combined with its industry and medical research
collaborations validate its leadership role in Cancer Detection,
Therapy and Cure.
Safe-Harbor Statement This release
contains statements or projections regarding future performance
that is forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those projected as a result of certain risks and
uncertainties. The company's filings contain various RISK FACTORS
(and are incorporated herein by reference) and should be read
before any investment decision.
ChromoCure, Inc. www.ChromoCure.com info@chromocure.com
Tel: 1.775.636.6548 1.775.636.6548 Genome Research Group,
Inc. www.genomeresearchgroup.com info@genomeresearchgroup.com
Tel: +011 (44) 20 7101 9475
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Sep 2023 to Sep 2024